Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences, Inc. - Common Stock (NQ: SAVA )

2.760 +0.150 (+5.75%)
Streaming Delayed Price Updated: 12:28 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
Cassava Sciences Stock Has Had an Epic Run, but Getting in Now Is a Serious Risk
SAVA stock has gone "to the moon" thanks to its Alzheimer treatment catalyst, but don't assume it's immune to a possible reversal. 
Via InvestorPlace
These Are the Top Reasons You Should Load Up on Cassava Sciences Stock
At the moment, there’s no cure for Alzheimer’s, but Cassava Sciences is working to wipe it out for good, making SAVA stock a buy here. 
Via InvestorPlace
With This Exciting Alzheimer’s Treatment, Cassava Sciences Stock Has Legs
Incredible Alzheimer's data suggests that Cassava has the right approach to tackling the disease powering SAVA stock. 
Via InvestorPlace
Cassaca Sciences Stock Is a Buy on the Strength of a Promising Alzheimer’s Drug
Skeptics are wrong about Cassava's Alzheimer's drug, as the drug's data is superb. Long-term investors should buy SAVA stock. 
Via InvestorPlace
Why Might Cassava Succeed With Its Alzheimer's Drug, When So Many Have Failed?
Alzheimer's research has been hampered by apparently mistaken ideas about what causes the disease. Cassava has a new theory about what's responsible -- and its drug is showing positive results. 
Via The Motley Fool
Understanding Cassava Sciences's Unusual Options Activity
Cassava Sciences (NASDAQ:SAVA) shares experienced unusual ... 
Via Benzinga
Unusual Options Activity Insight: Cassava Sciences
Cassava Sciences (NASDAQ:SAVA) shares experienced unusual... 
Via Benzinga
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease. 
Via The Motley Fool
How Much Should An Alzheimer's Drug Cost?
The answer is more complicated than you think. 
Via The Motley Fool
Navigating A Speculative Bubble
Invest while it inflates; protect before it pops. 
Via Talk Markets
Analyzing the Potential Risks of Cassava Sciences
Cassava Sciences has a promising drug candidate for Alzheimer's. However, SAVA stock may be overpriced based on the limited data so far. 
Via InvestorPlace
Why Is Cassava Sciences' Stock So Volatile?
The stock is up 1,700% year to date. 
Via The Motley Fool
Cassava Sciences vs. Biogen
Who will emerge victorious in the race to help Alzheimer's patients? 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Drops 50 Points; IEC Electronics Shares Spike Higher
Toward the end of trading Thursday, the Dow traded down 0.14% to 35,435.25 while the NASDAQ rose 0.29% to 14,808.42. The S&P also rose, gaining 0.19% to 4,456.37. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate
Cassava believes that a mutating protein, Filamin A, is a major culprit behind Alzheimer's disease. The company's drug, simufilam, aims to fix this mutation and restore its proper form and function. 
Via The Motley Fool
Bring a Neck Brace When Trading Cassava Sciences
Cassava is still pre-revenue but SAVA stock has a flock of strong fans. They bought the dip with gumption, which suggests long-term success. 
Via InvestorPlace
Why Shares of Cassava Sciences Fell 18.6% in July
The stock lost $75 a share in two days at the end of the month. 
Via The Motley Fool
What to Do After Cassava Sciences Dropped Off a Cliff
Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. 
Via InvestorPlace
Cassava Sciences May Be Revolutionary in the Alzheimer’s Fight
SAVA stock is truly worth paying attention to from here forward as data suggests Cassava Sciences may have solved a big mystery. 
Via InvestorPlace
3 Things About Cassava Sciences That Smart Investors Know
Things are changing, but the picture is getting more positive as time goes on. 
Via The Motley Fool
Cassava Sciences Stock Has Been Hammered For No Good Reason and Is Likely To Rebound
Cassava Sciences stock has been hammered for no good reason. SAVA stock is still worth over $900 given the positive 9-mo results of Simufilam. 
Via InvestorPlace
Why Former NYSE Trader David Green Bought NVIDIA, Tesla, and Cassava Sciences On Tuesday
Veteran trader David Green was back live trading on Benzinga Tuesday morning, and the lon... 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
75 Biggest Movers From Yesterday
Gainers Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares climbed 68.1% to close at $58.25 on Tuesday after the company announced that the it has received approval for a... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock increased by 35.01% to $5.5 during Monday's regular session. Trading volume for Xenetic Biosciences's stock is 10.1... 
Via Benzinga
48 Stocks Moving In Tuesday's Mid-Day Session
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures... 
Via Benzinga
A Forgettable Week For Alzheimer's Treatment Stocks: Two Of Our Top Names Come Back To Earth. This Is Why We Hedge.
Screen capture via Cassava Sciences' video for their Simufilam Alzheimer's disease treatment. Two Alzheimer's Names Come Back To Earth In a post last week (An... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers NanoVibronix (NASDAQ:NAOV) share... 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
Via Benzinga
63 Biggest Movers From Friday
Gainers ERYTECH Pharma S.A. (NASDAQ: ERYP) shares surged 55% to close at $6.37 on Friday after the company said the FDA has granted its eryaspase fast track designation for the... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
31 32 33 34 35 36 37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.